LOGIN  |  REGISTER
Amneal Pharmaceuticals
Terns Pharmaceuticals

Integra LifeSciences Leadership to Present at Wells Fargo and Morgan Stanley Healthcare Investor Conferences

August 29, 2025 | Last Trade: US$15.13 0.29 1.95

PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at two upcoming investor healthcare conferences:

  • Wells Fargo Healthcare Conference on September 3, 2025, at 12:45 p.m. ET
  • Morgan Stanley Healthcare Conference on September 10, 2025, at 8:30 a.m. ET

A live webcast of the presentations will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.

About Integra LifeSciences

At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands. For the latest news and information about Integra and its products, please visit www.integralife.com.

Investor Relations:
Chris Ward
(609) 772-7736
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Laurene Isip
(609) 208-8121
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page